191 GENERAL DISCUSSION 35. Hartstichting. Aantal nieuwe hart- en vaatpatiënten halveren met landelijke agenda [Internet]. 2024 [cited 2024 Feb 5]. Available from: https://www.hartstichting.nl/nieuws/ aantal-nieuwe-hart-en-vaatpatienten-halveren-met-landelijke-agenda 36. Hartstichting. Dit zijn de 7 uitdagingen van de hart- en vaatagenda. [Internet]. 2024 [cited 2024 Feb 5]. Available from: https://www.hartstichting.nl/wetenschappelijk-onderzoek/ hart-en-vaat-agenda?utm_source=linkedin&utm_medium=social&utm_campaign=hsretainer-jan&utm_content=hart-en-vaat-agenda 37. Drossman DA, Richter JE, Talley NJ. The functional gastrointestinal disorders: Diagnosis, pathophysiology, and treatment: A multinational consensus. 1st ed. Boston: Little Brown & Co; 1994. 38. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Vol. 45, Gut. BMJ Publishing Group; 1999. 39. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–91. 40. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–407. 41. Drossman DA, Hasler WL. Rome IV - Functional GI disorders: Disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257–79. 42. Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262–79. 43. Aprahamian I, Xue QL. Shaping the next steps of research on frailty: Challenges and opportunities. BMC Geriatrics. 2021;21(1):432. 44. nn. A study of milvexian versus apixaban in participants with atrial fibrillation (LIBREXIAAF). [Internet]. 2023 [cited 2024 Feb 2]. Available from: https://clinicaltrials.gov/study/ NCT05757869#more-information 45. nn. A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke (OCEANIC-AF). [Internet]. 2022 [cited 2024 Feb 2]. Available from: https://clinicaltrials.gov/study/NCT05643573 46. nn. Study to evaluate the efficacy and safety of abelacimab in high-risk patients with atrial fibrillation who have been deemed unsuitable for oral anticoagulation (LILAC-TIMI 76). [Internet]. 2022 [cited 2024 Feb 2]. Available from: https://clinicaltrials.gov/study/ NCT05712200 47. Euopean parliament and council. Regulation (EU) No 536/2014 of the European parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing directive 2001/20/ECI. [Internet]. 2014 [cited 2024 Feb 19]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32014R0536 48. Food and Drug Administration. Enhancing the diversity of clinical trial populations: Eligibility criteria, enrollment practices, and trial designs guidance for industry. [Internet]. 2020 [cited 2024 Feb 19]. Available from: https://www.fda.gov/media/127712/download 9
RkJQdWJsaXNoZXIy MTk4NDMw